Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections

Ana Cecilia Rodríguez, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Allan Hildesheim, Philip E Castle, Diane Solomon, Robert Burk, Proyecto Epidemiológico Guanacaste Group, Ana Cecilia Rodríguez, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Allan Hildesheim, Philip E Castle, Diane Solomon, Robert Burk, Proyecto Epidemiológico Guanacaste Group

Abstract

Health professionals and the public need to understand the natural history of human papillomavirus (HPV) infections of the cervix to best use the information provided by new molecular screening tests. We investigated outcomes of 800 carcinogenic HPV infections detected in 599 women at enrollment into a population-based cohort (Guanacaste, Costa Rica). For individual infections, we calculated cumulative proportions of three outcomes (viral clearance, persistence without cervical intraepithelial neoplasia grade 2 or worse [CIN2+], or persistence with new diagnosis of CIN2+) at successive 6-month time points for the first 30 months of follow-up. Cervical specimens were tested for carcinogenic HPV genotypes using an L1 degenerate-primer polymerase chain reaction method. Infections typically cleared rapidly, with 67% (95% confidence interval [CI] = 63% to 70%) clearing by 12 months. However, among infections that persisted at least 12 months, the risk of CIN2+ diagnosis by 30 months was 21% (95% CI = 15% to 28%). The risk of CIN2+ diagnosis was highest among women younger than 30 years with HPV-16 infections that persisted for at least 12 months (53%; 95% CI = 29% to 76%). These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages.

Figures

Figure 1
Figure 1
Clearance of carcinogenic human papillomavirus (HPV) infections during 30 months of follow-up. (A) All ages combined (n = 800 infections). (B) Women younger than 30 years (n = 393 infections). (C) Women aged 30 years or older (n = 407 infections). Carcinogenic types include HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, 82, 82v. The x-axes represent months of follow-up, and the y-axes represent the percentage of infections that cleared (unshaded), persisted without evidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+; stippled), or persisted with evidence of CIN2+ (solid shading). The 3-month data represent nonrandom samples (36% for A, 38% for B, and 34% for C).
Figure 2
Figure 2
Clearance of human papillomavirus type 16 infections during 30 months of follow-up. (A) All ages combined (n = 115 infections). (B) Women younger than 30 years (n = 55 infections). (C) Women aged 30 years or older (n = 60 infections). The x-axes represent months of follow-up, and the y-axes represent the percentage of infections that cleared (unshaded), persisted without evidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) (stippled), or persisted with evidence of CIN2+ (solid shading). The 3-month data represent nonrandom samples (38% for A, 44% for B, and 33% for C).

References

    1. Goldsmith MR, Bankhead CR, Kehoe ST, Marsh G, Austoker J. Information and cervical screening: a qualitative study of women’s awareness, understanding and information needs about HPV. J Med Screen. 2007;14(1):29–33.
    1. Jain N, Irwin K, Carlin L, Freeman C, Montano D, Kasprzyk D. Use of DNA tests for human papillomavirus infection by US clinicians, 2004. J Infect Dis. 2007;196(1):76–81.
    1. Tiro JA, Meissner HI, Kobrin S, Chollette V. What do women in the U.S. know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev. 2007;16(2):288–294.
    1. Waller J, Marlow LA, Wardle J. The association between knowledge of HPV and feelings of stigma, shame and anxiety. Sex Transm Infect. 2007;83(2):155–159.
    1. Brown D. Millions in U.S. infected with HPV. Washington Post. 2007 Feb 28;:A.1.
    1. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(suppl 1):S1–S15.
    1. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004;57(1):68–72.
    1. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1796–1807.
    1. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813–819.
    1. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papilloma-virus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–1079.
    1. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1):76–84.
    1. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191(2):182–192.
    1. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582–1589.
    1. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica. 1997;1(5):362–375.
    1. Bratti MC, Rodriguez AC, Schiffman M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica. 2004;15(2):75–89.
    1. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol. 2002;68(3):417–423.
    1. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol. 1997;35(6):1304–1310.
    1. Forslund O, Antonsson A, Nordin P, Stenquist B, Hansson BG. A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. J Gen Virol. 1999;80(pt 9):2437–2443.
    1. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197(4):356.e1–6.
    1. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2006;197(4):346–55.
    1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.
    1. Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis. 2003;30(7):581–587.
    1. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervicallesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489–498.
    1. Nohr B, Tabor A, Frederiksen K, Kjaer SK. Loop electrosurgical excision of the cervix and the subsequent risk of preterm delivery. Acta Obstet Gynecol Scand. 2007;86(5):596–603.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner